Synbiotic Health has announced that genomic evaluation and in vitro testing has revealed that its B. adolescentis iVS-1 probiotic strain produces Gamma-aminobutyric acid (GABA) and Folate (vitamin B9).
Synbiotic Health (Lincoln, Nebraska) has announced that a recent genomic evaluation and in vitro testing has revealed that its B. adolescentis iVS-1 probiotic strain produces Gamma-aminobutyric acid (GABA) and Folate (vitamin B9). The company explains in a press release that GABA is a neurotransmitter associated with stress reduction and sleep, while folate supports heart health as well as the growth and development of fetuses during pregnancy. Synbiotic Health says that its in vitro trials have shown that the probiotic strain produces three times more folate than other analyzed strains. Additionally, the folate it produces is more bioavailable compared to the folic acid found in most dietary supplements.
“These findings represent an important milestone for Synbiotic and our customers,” said Steve Prescott, Synbiotic’s chief commercial officer, in a press release. “Demonstrating that iVS-1 has the ability to produce both GABA and folate is an exciting development, since these metabolites are known to positively impact human health through multiple modes of action.”
“When taken together with the already known attributes of iVS-1, including its proliferation and persistence at high levels in the human gut, its ability to promote a bifidogenic response, and its capacity to promote healthy gut-barrier function all at low levels of supplementation (1 billion cfu/dose), iVS-1 becomes a strong addition to many probiotic products designed for a variety of health claims,” added Kevin Hooper, director of business development.
Synbiotic Health said in the press release that more research is currently underway to identify the genes responsible for beneficial health claims from the other strains it has identified via its proprietary strain selections: In Vivo Selection (iVS) and In Vitro Enrichment (iVE). These probiotics ingredients, the company says, will be developed and commercialized in its new 43,000 square foot facility which is scheduled to open in late 2023 and early 2024.
“We are extremely excited for the opportunity to commercialize these strains, and we are looking forward to future developments from our innovative, forward-thinking R&D team,” said Prescott in a press release. “Bringing new and impactful health benefits to market and to the consumer is what drives us at Synbiotic Health.”